Executive Interviews

31. Gene Therapy Developer Rocket Pharma Aims High 3/1/2023

    “From our first patient until now, all our manufactured drug product that has treated patients has been produced in partnership with CDMOs,” says Gaurav Shah, M.D., cofounder and CEO of Rocket Pharma.

32. Making The Right Deal For Biohaven 3/1/2023

    Biohaven CEO Vlad Coric describes the events leading up to Pfizer’s $11.6 billion acquisition, his drug launch during the start of COVID-19, and why company titles and seniority don’t really matter.

33. Translating Nobel Prize Winning Science Into Medicine 3/1/2023

    2022 Nobel Prize winner Carolyn Bertozzi discusses her approach to translating scientific discoveries into biopharmaceutical products, and her ongoing partnership with Shasqi CEO José Mejía Oneto.

34. Why Takeda Is Focusing So Much On Plasma-Derived Therapies 2/1/2023

    Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.

35. With Fundraising, A Track Record Matters: GeoVax's David Dodd 2/1/2023

    Industry veteran David Dodd, chairman and CEO at GeoVax, answers questions about the fundraising environment for small biotechs, and the dangers of toxic warrants.

36. Verve Therapeutics: How To Build A Gene Editing Biotech 1/3/2023

    Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.

37. Executive Outlook: Crafting New Solutions For Persisting Problems 12/1/2022

    Creativity will be in high demand, not just to control costs during tough economic conditions, but in key functional areas like business development and external collaboration, ESG (environmental, social, and governance), and diversity, equity and inclusion (DE&I).

38. A More Balanced And Stable Future With CDMOs 12/1/2022

    Two Industry Experts talk about where they see the outsourcing industry going in the near future.

39. Will The Finance And Funding Pendulum Swing Back To Black In 2023? 12/1/2022

    Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.

40. Biopharma Public Opinion, Pricing, Politics 12/1/2022

    Biopharma sustainability will require the industry not shy from public opinion, but meet it head on. To win short-term battles, however impressively as with creation of the COVID vaccines, may not be enough to secure total victory.